Targeting the Toll-Like Receptor/Interleukin 1 Receptor Pathway in Human Diseases: Rational Design of MyD88 Inhibitors
Clinical Lymphoma, Myeloma and Leukemia - United States
doi 10.1016/j.clml.2013.02.003
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2013
Authors
Publisher
Elsevier BV